Will AI Revolutionize Drug Development? These Are the Root Causes of Drug Failure It Must Address
1 min read
Summary
While 90% of drugs going through clinical trials fail, some pharmaceutical companies and researchers are keen to use AI to speed up the drug development process and improve success rates, according to an article in Singularity Hub.
However, others working in the industry are more sceptical, claiming that the impact of such technology is unclear and that any datasets generated from AI-generated drugs are of low quality.
The article suggests current drug development processes are overly focused on less critical aspects, with researchers and scientists failing to identify major problems that cause drug failures.
Dr Christian Macedonia and Dr Duxin Sun suggest an AI system could be developed to predict dosage, safety and efficacy and used to test drugs on patients with both severe and mild symptoms of the targeted diseases.
They propose a model that could test AI-generated drugs using ultra-low doses in patients, which could help identify the best candidates while also reducing the cost of clinical trials.